Pierre-Georges Roy

Partner, CG Results US, Americas
Healthcare, Technology

Pierre joined Results in 2014 and oversees the growth of our US Healthcare business.

Pierre has 22 years of experience advising large public corporations as well as high growth and entrepreneurial companies in the converging sectors of healthcare and technology. His coverage includes Healthcare Commercialization & Communications, Healthcare Technology and Services, and Performance Marketing.

Pierre has specific experience leading complex, multijurisdictional transactions in which cultural and long-term mission alignment are paramount to the success of the combination. He has worked on transactions with Microsoft, Accenture, S&P, News Corp, AT&T, Orange, Hearst, Sony as well as many of the world’s leading private equity funds.

Earlier in his career, Pierre worked as a project finance lawyer at Clifford Chance, one of the “Magic Circle” of leading British law firms where he worked on telecom financings in Central & Eastern Europe and in Latin America. He later joined The Zanett Group, a New York based hedge fund where he was a Partner, to run a direct investment strategy to make buyout investments in U.S. IT Services firms.

Pierre co-founded and sold two businesses to U.S. publicly listed buyers. Emergingcast, a digital content production platform, sold to Demand Media (NYSE), and Rootaxcess, an enterprise cloud solutions provider, sold to Fusion Telecom (NASDAQ).

Pierre holds a law degree from McGill University where he served as Managing Editor of the Law Journal. He is fluent in French and Spanish.

A fitness enthusiast, Pierre practices martial arts, cycling, tennis and skiing. He is married, with two sons and an English springer spaniel called “Junior Roy”.

Recent Transactions

Latest Insights

17th May 2021

The next chapter: Changing market dynamics in commercialisation and medical communications

The last twelve months have been a time of extraordinary activity in the commercialisation sector – the COVID-19 pandemic saw medcomms groups play a crucial part in keeping pharma companies connected with patients and healthcare professionals, and dealmaking was frenetic on both sides of the Atlantic, for smaller agencies as well as for emerging ‘CCOs’. […]

29th May 2020

The future of private equity investment in healthcare

Private equity investment in healthcare has been a driving force behind growth in the sector in recent years (read our article on the topic), and despite COVID-19, the capital available for investment is at record levels. Structural change will always create opportunity as well as challenges, and private equity should be well placed to help […]

15th May 2020

Virtual deal-making – a new normal for the M&A world

Towards a brave new “all-In” virtual deal-making world Once obligatory rituals of the investment process, the “gut check” in-person meeting between a buyer and the operator-sellers are now being replaced with video conference interviews and virtual facility tours (and the detailed physical inspection of the workplace and core scientific R&D facilities). In this paper, we […]

29th November 2019

Genomics: a source of future deal activity for the US

“Living in a world where a human genome can be sequenced for $100 is a future companies are increasingly preparing for by pursuing M&A and capital raising transactions.” Predicting an individual’s health has become a key area of focus as healthcare companies attempt to determine and reduce total lifetime healthcare costs for patients. The most […]

5th October 2017

How Technology Titans are Tackling a 3 Trillion Dollar Opportunity – Google, Amazon, and Apple Move into U.S. Healthcare

Having transformed the way we connect, shop and entertain ourselves, Alphabet (parent company of Google), Amazon, and Apple are now making big bets on bringing transformative technology to another aspect of our lives, health. The three technology giants are gaining a significant foothold in the $3 trillion US healthcare market and have started activating their […]